FLT3 and acute myeloid leukemia: Ohanian et al. conducted a study including 27 newly diagnosed, treatment‐naïve patients with FLT3‐mutated AML who received first‐line therapy with a combination of 5‐azacytidine (AZA) and sorafenib.